Vistagen Therapeutics, Inc. (VTGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. on April 13, 2026, covering events occurring on April 7, 2026. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation awards and does not contain financial performance data.
Material Changes
On April 7, 2026, the Compensation Committee approved retention awards in the form of stock options for all Company employees. Specific grants were made to five executive officers:
- Recipients: Shawn K. Singh (CEO), Reid G. Adler (CLO), Elissa S. Cote (CCDO), Joshua S. Prince (COO), and Nick B. Tressler (CFO).
- Award Size: Each executive received options to purchase up to 75,000 shares of common stock.
- Exercise Price: $0.5358 per share.
- Vesting Schedule: 25% vests six months after the grant date, with the remainder vesting in 25% installments every six months thereafter, achieving full vesting on the two-year anniversary.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The awards are subject to the terms of the Amended and Restated 2019 Omnibus Equity Incentive Plan.
Investor Verification Checklist
- Verify the total number of shares reserved under the 2019 Omnibus Equity Incentive Plan to assess dilution impact.
- Confirm the current market price of VTGN common stock relative to the $0.5358 exercise price.
- Review the full award agreements for specific performance conditions or termination clauses not detailed in this summary.